Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi PharmaTech | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

WuXi PharmaTech

Lab and manufacturing revenues on the rise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 2Q10

2Q Revenues: $81 million (+21%)

2Q Earnings: $14 million (-6%)

YTD Revenues: $162 million (+28%)

YTD Earnings: $29 million (+11%)

Comments: Lab services in China brought in $53 million in 2Q10 revenues (+18%), while U.S. lab services were up 19% to $20 million. For 1H10, China lab services were $103 million (+19%) and U.S. lab revenues were $37 million (+17%). Manufacturing services, which are based in China were up 55% in 2Q10 to $8.5 million and up 175% for 1H10 to $22 million, driven by demand for clinical trial supplies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters